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Brief report
Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9
on sensitivity to acenocoumarol
Jose´ Hermida, Jose´ Zarza, Ignacio Alberca, Ramo´n Montes, Marı´a Luz Lo´pez, Eva Molina, and Eduardo Rocha
The 2C9*3 and 2C9*2 polymorphisms of
cytochrome P-450 CYP2C9 are associ-
ated with hypersensitivity to warfarin and
bleeding. The effect of these polymor-
phisms on sensitivity to acenocoumarol
is unknown. Three groups of patients,
with low, medium, or high acenocoumarol-
dose requirements, were studied. Age
influenced the acenocoumarol sensitiv-
ity. Bearing the 2C9*3 allele was associ-
ated with the need for a lower acenocou-
marol dose (odds ratio [OR], 6.02; 95%
confidence interval [CI], 1.50-24.18); 80%
of carriers of the 2C9*3 allele required a
low dose. The 2C9*2 allele was associ-
ated with a lower acenocoumarol-dose
requirement (OR, 2.70; 95% CI, 1.11-6.58)
because of a reduced risk of the need for
a high acenocoumarol dose (4.8% of the
patients in the high-dose group carried
the 2C9*2 allele versus 34.1% and 30.2%,
respectively, in the medium-dose and low-
dose groups). Therefore, carriers of 2C9*3
may need a low initial loading dose of
acenocoumarol. Because acenocoumarol
sensitivity with the 2C9*2 variant does
not seem to be clinically relevant, the
drug could be an alternative to warfarin in
2C9*2 carriers. (Blood. 2002;99:4237-4239)
© 2002 by The American Society of Hematology
Introduction
Oral anticoagulant therapy with coumarin derivatives is used
broadly to prevent recurrent arterial and venous thrombosis. The
response to coumarin derivatives depends on several factors,
such as sex, age, diet, interacting drugs, and probably other
unknown individual and ethnic factors.1,2 Warfarin is the main
coumarin derivative used in the United Kingdom and United
States. The biotransformation and subsequent elimination of
warfarin are due mainly to oxidation by cytochrome P-450
CYP2C9. Recently, 2 variant alleles of this cytochrome that
reduce in vitro enzymatic activity have been identified: 2C9*2
(Arg144Cys) and 2C9*3 (Ile359Leu).3,4 These variant alleles
have been strongly associated with increased sensitivity to
warfarin and, less clearly, with the risk of bleeding during
anticoagulant treatment.5-7
Acenocoumarol is a coumarin derivative used widely for oral
anticoagulant therapy in many European and Latin American
countries. Mannucci8 has suggested that acenocoumarol be used
instead of warfarin in patients carrying the hyperresponsive
alleles 2C9*2 and 2C9*3. Acenocoumarol, like warfarin, is
administrated as a racemate mixture of (R)- and (S)-acenocou-
marol. Cytochrome P-450 CYP2C9 is involved in the oxidation
of both enantiomers, whereas cytochrome P-450 CYP2C19 acts
on (R)-acenocoumarol only.9 Because the (S)-enantiomer is
more active than the (R)-enantiomer, allelic variations of
cytochrome P-450 CYP2C9 could play an important role
in sensitivity to acenocoumarol. In this context, the 2C9*3
allele has been linked to raised plasma levels of (S)-
acenocoumarol in a small group of patients with low acenocou-
marol requirements.10
Because of the broad clinical use of acenocoumarol in many
countries and the possible use of acenocoumarol as an alterna-
tive to warfarin in patients bearing the 2C9*2 and 2C9*3
variants, we studied the role of these polymorphisms in
modulating the acenocoumarol requirement in patients receiv-
ing anticoagulation treatment.
Study design
Patients
The study included 113 outpatients attending the Hospital Clı´nico
Universitario de Salamanca, Spain, who had been receiving a stable
acenocoumarol dose for at least 3 months to achieve an International
Normalized Ratio between 2 and 3.2. The patients were classified into
the following 3 groups according to the acenocoumarol dose prescribed
in the previous month: a group of 43 consecutive patients with low dose
requirements ( 7 mg/week), a group of 45 consecutive patients with
medium dose requirements ( 7 mg and  28 mg/week), and a group of
21 consecutive patients with high dose requirements ( 28 mg/week).
Age, sex, weekly dose required, and intake of drugs affecting acenocou-
marol metabolism were recorded. Two patients with liver disease and 2
with thyroid disease were excluded from the study. The percentages of
patients in the low-, medium-, and high-dose acenocoumarol groups in
the whole population of patients receiving anticoagulation treatment
were 11%, 83.5%, and 5.5%, respectively. All subjects gave informed
consent to participation in the study.
Genotyping
Genotyping for the 2C9*3 and 2C9*2 alleles was done by using
polymerase chain reaction followed by digestion with restriction en-
zymes according to methods previously described,6 with minor changes.
The primers used for 2C9*3 analysis were 5-TGCACGAGGTCC-
AGAGATGC-3 and 5-AATGATACTATGAATTTGGGACTT CGA-3,
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and the restriction enzyme was NsiI. The primers used for 2C9*2 analysis
were 5-CAATGGAAAGAAATGGAAGGAGGT-3 and 5-GACTCATA-
ATGAAAGATATG-3, and the restriction enzyme was AvaII.
Statistical analysis
Dose was treated as an ordinal variable (low, medium, and high). Values
for age and dose, when analyzed as a continuous variable, were
expressed as means  SD. A multivariate ordered logistic regression
model was used to assess the effect of allelic variants and age
(independent variables) on the acenocoumarol requirement. Thus, the
relation between the ordinal variable dose (low, medium, or high) and
allelic variants and age could be established, with controlling for sex and
use of other drugs.11 The adequacy of the model was assessed by using
the Pearson goodness-of-fit test. Subjects heterozygous and homozy-
gous for the allelic variants were included in the same category because
of the low prevalence of homozygous subjects. One-way analysis of
variance was used to compare age between groups. Differences in the
acenocoumarol requirement between patients who were carriers and
noncarriers of the 2C9*3 allele in the low-dose group were assessed
with the Student t test. Statistical analyses were done with SPSS
software (version 10.0; SPSS, Chicago, IL).
Results and discussion
Fifteen of 108 patients carried the 2C9*3 allele, with 14 being
heterozygous and one homozygous; one patient could not be
analyzed. Twenty-nine of 108 patients carried the CYP2C9*2
allele, with 26 being heterozygous and 3 homozygous; one patient
could not be analyzed (Table 1). Three patients in the low-dose
group and one in the medium-dose group were double heterozy-
gous. No double-heterozygous patients were found in the high-dose
group. The mean age in the low-, medium-, and high-dose groups
was significantly different (74.3  7.7 years, 65.7  10.5 years,
and 58.3  11.0 years, respectively; P  .001).
We analyzed the effect of 2C9*3 and 2C9*2 variants, age,
sex, and interacting drugs by using a multivariate ordered
logistic regression model. Neither sex nor drugs affected the
acenocoumarol requirement. This finding could have been due
to the low number of patients taking other drugs: only 14
patients were taking metabolism-decreasing drugs (8 in the
low-dose, 3 in the medium-dose, and 3 in the high-dose group)
and only 2 were taking metabolism-increasing drugs (one in the
low-dose and one in the high-dose group). Because there were
no significant interactions among the analyzed variables (data
not shown), the final model was formed by using 2C9*3 and
2C9*2 variants and age (Table 2).
Age was an important factor modulating the sensitivity to
acenocoumarol. For every year of age, there was a 12% increase in
the risk of needing a lower acenocoumarol dose (odds ratio [OR],
1.12; 95% confidence interval [CI], 1.07-1.17).
Carrying the 2C9*3 allele was an important independent
factor modulating the sensitivity of patients to the anticoagulant
effect of acenocoumarol. Patients with this allele were at a
higher risk of needing a lower dose of acenocoumarol than
patients without this variant (adjusted OR, 6.02; 95% CI,
1.50-24.18). This effect was due mainly to the remarkable
number of carriers of the 2C9*3 allele among the patients in the
low-dose group. Eighty percent of patients carrying at least one
2C9*3 allele had a very low acenocoumarol requirement ( 7
mg/week); moreover, the mean weekly dose of acenocoumarol
required by patients in the low-dose group with at least one
2C9*3 allele was lower than that of patients in the same group
without this allelic variant (5.04  1.26 mg versus 6.15  0.94
mg; P  .04). Together, these results suggest a remarkable
effect of the 2C9*3 allele on sensitivity to acenocoumarol,
possibly one even greater than the previously observed effect on
warfarin metabolism.5,6 This finding could be relevant applied to
clinical practice: because it has been suggested that hyperrespon-
siveness to warfarin is linked to a high risk of bleeding at the
beginning of treatment, patients bearing the 2C9*3 allele that
are to be treated with acenocoumarol should start treatment with
a reduced initial loading dose to avoid overanticoagulation and
subsequent bleeding risk.
The 2C9*2 variant also played an independent and signifi-
cant role on patients’ sensitivity to acenocoumarol. Carrying at
least one 2C9*2 allele also increased the risk of requiring a
lower dose of acenocoumarol (OR, 2.70; 95% CI, 1.11-6.58).
Interestingly, this effect was due mainly to the remarkably
reduced risk of needing an acenocoumarol dose higher than 28
mg/week when this variant was present: only 4.8% of patients in
the high-dose group carried the 2C9*2 allele, whereas it was
present in 34.1% of patients in the medium-dose group and
30.2% in the low-dose group. Nevertheless, the effect of the
2C9*2 allele on the acenocoumarol requirement was much
smaller than the effect exerted by the 2C9*3 allele. In the
clinical setting, because the 2C9*2 allele has been described as a
major factor conditioning warfarin sensitivity, it may be advis-
able for patients bearing the 2C9*2 allele to start anticoagulant
treatment with acenocoumarol instead of warfarin to avoid
overanticoagulation risk and subsequent bleeding.5-7
In conclusion, we demonstrated that the 2C9*3 allele impor-
tantly and independently modulates sensitivity to acenocou-
marol, a finding indicating that a reduced initial loading dose of
acenocoumarol should be used in carriers of this allele. The
weak effect on acenocoumarol sensitivity exerted by the 2C9*2
allele makes this drug a potential alternative to warfarin in
patients carrying this variant.
Table 1. Frequencies of cytochrome P-450 2C9 allelic variants in patients with
different acenocoumarol-dose requirements
Variant
Low dose
(n 43)
Medium dose
(n 45)
High dose
(n 21)
CYP2C9*1/*1 30 (71.4) 43 (95.6) 20 (95.2)
CYP2C9*1/*3 11 (26.2) 2 (4.4) 1 (4.8)
CYP2C9*3/*3 1 (2.4) — —
CYP2C9*1/*1 30 (69.8) 29 (65.9) 20 (95.2)
CYP2C9*1/*2 11 (25.6) 14 (31.8) 1 (4.8)
CYP2C9*2/*2 2 (4.6) 1 (2.3) —
Values are numbers (%) of patients.
Table 2. Adjusted odds ratios for 2C9*3 and 2C9*2 variants and patient age
Variable Adjusted OR 95% CI P*
CYP2C9*3 6.02 1.50-24.18 .0114
CYP2C9*2 2.70 1.11-6.58 .0284
Year of age 1.12 1.07-1.17  .0001
Adjusted ORs are measurements of being at risk of needing a lower dose of
acenocoumarol when carrying an allelic variant or when being 1 year older.
Patient sex and use of other drugs were finally excluded from the multivariate
model because they did not show significant effects (P  .41 and P  .56,
respectively) or play a role in any interactions.
CI indicates confidence interval. *On Wald testing.
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